Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign
Stocks in this Quantisnow insightHealth Care
Historical context for SUPN
Across the 20 sessions after earlier SUPN headlines, the stock closed higher 13 times and lower 5 times, with a median move of 1.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SUPN | SPY |
|---|---|---|---|
| Oct 22, 2026 | Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) | +2.1% | -1.2% |
| Oct 19, 2026 | Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 | +5.2% | +0.4% |
| Sep 3, 2026 | Supernus Pharmaceuticals to Participate in September Investor Conferences | -0.1% | +1.0% |
| Aug 31, 2026 | Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD | +1.1% | -0.3% |
| Aug 3, 2026 | Supernus Announces Second Quarter 2026 Financial Results | +3.1% | +1.4% |
| Jul 23, 2026 | Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 | +0.5% | -1.2% |
Quantisnow market dataNASDAQ
SUPN
Supernus Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2012
Get push alerts for SUPN
Full SUPN profile on Quantisnow Follow SUPN and get a push notification the moment its next story breaks.